[CLSTR]
< Back to situations

[ORGANIZATION]

Truist Financial

Featured in 14 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [US] [ID]

CoreWeave expansion and financial scrutiny persist

15 clusters · 36 sources · last updated

Latest: CoreWeave receives $107 million investment from Appaloosa Management

CoreWeave’s shares have faced volatility as investors weigh massive capital expenditures against rapid revenue growth. Following a second-quarter revenue report of $2.58 billion—a 112% year-over-year increase—the company

[ACTIVE] [BUSINESS] [US] [GB] [DE]

Palantir AI growth, earnings surge, and geopolitical debate

47 clusters · 152 sources · last updated

Latest: Nebius Group shares rise on Palantir partnership and AI growth

Palantir’s AI-driven platforms continue to secure commercial and government contracts. In the second quarter of 2026, the company reported revenue of $1.935 billion, a 93% year-on-year increase, with earnings per share o

[ACTIVE] [BUSINESS] [US]

SoFi stock fluctuates amid record earnings and crypto pivot

18 clusters · 31 sources · last updated

Latest: SoFi Technologies reports surging membership and institutional investment

SoFi Technologies continues to report record financial results following its Q2 2026 earnings, though its stock price remains under pressure. While the company reported revenue of approximately $1.2 billion—a 40% year-ov

[QUIET] [BUSINESS] [BE] [US]

PagerDuty financial performance and market activity

2 clusters · 2 sources · last updated

Latest: PagerDuty scheduled to release Q2 2027 earnings

PagerDuty experienced a rise in share price following a quarterly earnings report that beat estimates, with earnings of $0.32 per share and revenue of $120.97 million. During this period, institutional investors such as

[QUIET] [BUSINESS] [US]

Sionna Therapeutics cystic fibrosis drug trial failure

2 clusters · 4 sources · last updated

Latest: Vertex Pharmaceuticals maintains cystic fibrosis market lead after Sionna Therapeutics trial failure

Sionna Therapeutics discontinued its experimental cystic fibrosis drug, SION-719, after a mid-stage clinical trial failed to show meaningful benefits. The trial, which tested the drug as an adjunctive treatment alongside

[QUIET] [BUSINESS] [US]

Institutional investment and market activity updates

2 clusters · 3 sources · last updated

Latest: Institutional investors increase stakes in EOG Resources and AMD

Recent SEC filings reveal various institutional investment activities across multiple sectors. S&CO Inc. has expanded its portfolio through acquisitions in Okta, Inc., Airbnb, Inc., and EOG Resources, Inc. In the semico

Also covered in